Axovant Sciences Ltd (AXON.OQ)
20 Nov 2017
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|57||2017||President, Chief Operating Officer|
|60||2017||Chief Executive Officer, Director|
|46||2015||Chief Financial Officer|
|31||2017||Director, Chief Executive Officer - Roivant Sciences|
|56||President of Axovant Sciences GmbH and Chief Commercial Officer|
- BRIEF-Axovant announces second fiscal quarter results
- UPDATE 3-Axovant to pull plug on Alzheimer's drug after key study fails
- BRIEF-Roivant Sciences statement on mindset results
- BRIEF-Axovant announces negative topline results of intepirdine phase 3 mindset trial in Alzheimer's disease
- Axovant's Alzheimer's drug fails late-stage trial